ReviewInternational journal of radiation oncology, biology, physics2011
The evolving role of radiation therapy in the management of malignant melanoma.
Review in International journal of radiation oncology, biology, physics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 69 citations in OpenAlex.
- Clinical Management of Multiple Melanoma Brain Metastases: A Systematic Review.JAMA oncology · 2015Pooled it
- Sinonasal Mucosal Melanoma: A Comprehensive Review and Clinical Experience.Journal of rhinology : official journal of the Korean Rhinologic Society · 2025Review
- A rare case of brain metastatic malignant melanoma coexisting with black colored dura mater: Management in low-resource setting.Surgical neurology international · 2025Article
- Targeted Radionuclide Therapy Decreases Melanoma Lung Invasion by Modifying Epithelial-Mesenchymal Transition-Like Mechanisms.Translational oncology · 2019Article
- The Benefit of Reactivating p53 under MAPK Inhibition on the Efficacy of Radiotherapy in Melanoma.Cancers · 2019Article
- HDAC2 Inhibitor Valproic Acid Increases Radiation Sensitivity of Drug-Resistant Melanoma Cells.Medical sciences (Basel, Switzerland) · 2019Article
- Twice-daily Radiation for Metastatic Malignant Melanoma: A Different Approach Resulting in a Significant Response.Cureus · 2019Article
- Combining the DNA Repair Inhibitor Dbait With Radiotherapy for the Treatment of High Grade Glioma: Efficacy and Protein Biomarkers of Resistance in Preclinical Models.Frontiers in oncology · 2019Article
- Carbon ion irradiation abrogates Lin28B-induced X-ray resistance in melanoma cells.Journal of radiation research · 2017Article
- Article
- Article
- The influence of postoperative lymph node radiation therapy on overall survival of patients with stage III melanoma, a National Cancer Database analysis.Melanoma research · 2016Article
- Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial: A TITE-CRM Phase I/II Clinical Trial.Translational oncology · 2016Article
- Comparative Aspects of Canine Melanoma.Veterinary sciences · 2016Review
- BRAF inhibitors and radiotherapy for melanoma brain metastases: potential advantages and disadvantages of combination therapy.OncoTargets and therapy · 2016Review
- Two heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases.Neuro-oncology · 2015Review
- Modulation of radiochemoimmunotherapy-induced B16 melanoma cell death by the pan-caspase inhibitor zVAD-fmk induces anti-tumor immunity in a HMGB1-, nucleotide- and T-cell-dependent manner.Cell death & disease · 2015Article
- The role of radiotherapy in the management of sinonasal melanoma and its impact on patients and healthcare professionals.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2014Review
- A preclinical study combining the DNA repair inhibitor Dbait with radiotherapy for the treatment of melanoma.Neoplasia (New York, N.Y.) · 2014Article
- CTC1 increases the radioresistance of human melanoma cells by inhibiting telomere shortening and apoptosis.International journal of molecular medicine · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
The incidence of melanoma is rising in the United States, leading to an estimated 68,720 new diagnoses and 8,650 deaths annually. The natural history involves metastases to lymph nodes, lung, liver, brain, and often to other sites. Primary treatment for melanoma is surgical excision of the primary tumor and affected lymph nodes. The role of adjuvant or definitive radiation therapy in the treatment of melanoma remains controversial, because melanoma has traditionally been viewed as a prototypical radioresistant cancer. However, recent studies suggest that under certain clinical circumstances, there may be a significant role for radiation therapy in melanoma treatment. Stereotactic radiosurgery for brain metastases has shown effective local control. High dose per fraction radiation therapy has been associated with a lower rate of locoregional recurrence of sinonasal melanoma. Plaque brachytherapy has evolved into a promising alternative to enucleation at the expense of moderate reduction in visual acuity. Adjuvant radiation therapy following lymphadenectomy in node-positive melanoma prevents local and regional recurrence. The newer clinical data along with emerging radiobiological data indicate that radiotherapy is likely to play a greater role in melanoma management and should be considered as a treatment option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.